Filing Flows › Health Care › CervoMed (CRVO)
CervoMed (CRVO) earnings and revenue breakdown
Latest: Q4 2025 · 10-K filed Mar 13, 2026 · CervoMed (CRVO) Q4 2025 earnings results →
Q4 2025 Revenue down 100% year over year to $9K
CervoMed made $9K in Q4 2025 (-100% Y/Y). Operating margin n/m, net loss $8.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9K in Q4 2025, down 100% year over year and down 97% from the previous quarter.
Operating costs exceeded revenue by $8.3M, an operating margin of -95479.2%. Total costs fell 11% while revenue fell 100%. The quarter ended with a net loss of $8.1M, wider than the previous quarter's $7.7M loss.
Operating cash flow was −$6.6M. Non-cash charges added back $299K of share-based compensation. Working capital and other items added $1.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 10-K | Mar 13, 2026 | $9K | -100% | n/m | −$8.1M | −$6.6M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $323K | -83% | n/m | −$7.7M | −$6.5M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $1.8M | -47% | -376.4% | −$6.3M | −$6.5M |
| Q1 2025 | 10-Q | May 12, 2025 | $1.9M | -18% | -276.6% | −$4.9M | −$3.9M |
| Q4 2024 | 10-K | Mar 17, 2025 | $2.2M | -13% | -334.9% | −$6.7M | −$8.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB.
In its own words, from its 8-K, filed Aug 10, 2026.
CervoMed against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -100% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CRVO CervoMed | Q4 2025 | $9K | -100% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: CervoMed 10-K on SEC EDGAR · CIK 1053691 · Pharmaceutical Preparations
13F: who owns CRVO and who is buying
More on CRVO
History
Every quarter: Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results